Compare S&P500 ETF (SPY) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P500 ETF vs State Street SPDR S&P Biotech ETF — how do they compare? S&P500 ETF trades at $778.54 (market cap $821.54B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: S&P500 ETF is far larger — about 81.3× State Street SPDR S&P Biotech ETF's market cap, and S&P500 ETF is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold S&P500 ETF for 205 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| SPY | XBI | |
|---|---|---|
Market Cap | $821.54B | $10.11B |
Volume | 40,070,358 | 12,903,266 |
52-Week High | $779.14 | $169.55 |
52-Week Low | $631.99 | $104.99 |
Typical Hold Time | 205 Days | 38 Days |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPY, tracking the S&P 500, trades at $773.97, down 0.42% on the day amid mixed market signals. Technical indicators show a bullish trend with moving averages supporting upside momentum, while oscillators remain neutral. The ETF's fundamentals are tied to the broad U.S. equity market, with no specific company financials available, and a future dividend of $1.89 scheduled for October 2026. Recent news highlights concerns over valuation and profit growth expectations for 2027.
The outlook for SPY is cautiously optimistic, driven by bullish technical trends and seasonal patterns, but risks include potential earnings growth slowdown and elevated market valuations. Investors may find opportunity in broad market exposure, though vigilance on macroeconomic indicators and corporate profit trends is warranted.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
